[CH3:1][C:2]1([C:8]([OH:10])=O)[CH2:7][CH2:6][CH2:5][CH2:4][CH2:3]1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.C(N(CC)CC)C.[N:42]1[C:43]([C:51]([O:53][CH2:54][CH3:55])=[O:52])=[CH:44][N:45]2[CH2:50][CH2:49][NH:48][CH2:47][C:46]=12>ClCCCl.O.CN(C=O)C.C(Cl)Cl>[CH3:1][C:2]1([C:8]([N:48]2[CH2:49][CH2:50][N:45]3[CH:44]=[C:43]([C:51]([O:53][CH2:54][CH3:55])=[O:52])[N:42]=[C:46]3[CH2:47]2)=[O:10])[CH2:3][CH2:4][CH2:5][CH2:6][CH2:7]1To a vial was added 1-methyl-1-cyclohexanecarboxylic acid (0.024 g, 0.168 mmol), HATU (0.064 g, 0.168 mmol), triethylamine (0.134 mL, 0.96 mmol), DCM (2 mL), and DMF (0.2 mL). After shaking for 30 min, ethyl 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate (0.031 g, 0.16 mmol) was added. The mixture was shaken at rt for 16 h. To the vial was added water (1 mL) and DCE (1 mL). After separation, the aqueous layer was extracted with DCE twice (3 mL). The combined organic layers were concentrated to give crude ethyl 7-(1-methylcyclohexanecarbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate as a solid.
読み込み中…
